Assay-guided therapy can improve survival in patients with recurrent, high-grade glioma, according to a phase 3 study presented in a poster at the AACR Annual Meeting 2022.
Patients who received treatment selected by the ChemoID assay had superior progression-free survival (PFS) and overall survival (OS), when compared with patients who received physician’s choice of therapy.
The ChemoID assay was designed to select treatments that will target the bulk of tumor cells as well as therapy-resistant cancer stem cells.
The phase 3 trial (ClinicalTrials.gov Identifier: NCT03632135) enrolled patients with recurrent, grade III/IV glioma who had failed standard therapy. They were assigned to ChemoID assay-guided therapy or physician’s choice of therapy. Patients were treated until unacceptable toxicity, hospice, or death.
At the first planned interim analysis, 50 patients had been analyzed, and the median follow-up was 9 months. There were no significant differences in patient characteristics between the treatment arms.
There was a 3.5-month improvement in median OS with the assay-guided therapy. The median OS was 12.5 months in the ChemoID group and 9 months in the physician’s choice group (hazard ratio [HR], 0.44; 95% CI, 0.24-0.81; P =.008).
PFS was improved with the assay as well. The median PFS was 10.1 months for the assay-guided group and 3.5 months for the physician’s choice group (HR, 0.25; 95% CI, 0.14-0.44; P <.001).
The researchers noted that physicians actually picked the ChemoID-selected therapy for 13 of 23 patients in the physician’s choice group. When the researchers combined the survival data of these 13 patients with data from the ChemoID group, OS was prolonged by 8.0 months (as opposed to 3.5 months).
The rate of grade 3-4 chemotherapy-related adverse events was similar between the ChemoID and physician’s choice groups (26% and 38%, respectively).
The researchers said there were no unexpected neurologic chemotherapy-related adverse events or treatment-related deaths.
Based on these results, the researchers concluded that selection of treatment with the ChemoID assay represents “a feasible and promising strategy” to improve treatment for patients with recurrent, high-grade glioma.
Disclosures: This research was supported by Cordgenics, LLC. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Ranjan T, Sengupta S, Yu A, et al. Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade gliomas (NCT03632135). Presented at AACR 2022; April 8-13, 2022. Abstract CT224/3.
This article originally appeared on Cancer Therapy Advisor